{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:48:04Z","timestamp":1788497284179,"version":"build-2803163510"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>It has been hypothesized that polypharmacy may increase the frequency of multidrug interactions (MDIs) where one drug interacts with two or more other drugs, amplifying the risk of associated adverse drug events (ADEs). The main objective of this study was to determine the prevalence of MDIs in medication lists of elderly ambulatory patients and to identify the medications most commonly involved in MDIs that amplify the risk of ADEs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Medication lists stored in the electronic health record (EHR) of 6,545 outpatients \u226560 years old were extracted from the enterprise data warehouse. Network analysis identified patients with three or more interacting medications from their medication lists. Potentially harmful interactions were identified from the enterprise drug-drug interaction alerting system. MDIs were considered to amplify the risk if interactions could increase the probability of ADEs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>MDIs were identified in 1.3\u2009% of the medication lists, the majority of which involved three interacting drugs (75.6\u2009%) while the remainder involved four (15.6\u2009%) or five or more (8.9\u2009%) interacting drugs. The average number of medications on the lists was 3.1 \u00b1 2.3 in patients with no drug interactions and 8.6 \u00b1 3.4 in patients with MDIs. The prevalence of MDIs on medication lists was greater than 10\u2009% in patients prescribed bupropion, tramadol, trazodone, cyclobenzaprine, fluoxetine, ondansetron, or quetiapine and greater than 20\u2009% in patients prescribed amiodarone or methotrexate. All MDIs were potentially risk-amplifying due to pharmacodynamic interactions, where three or more medications were associated with the same ADE, or pharmacokinetic, where two or more drugs reduced the metabolism of a third drug. The most common drugs involved in MDIs were psychotropic, comprising 35.1\u2009% of all drugs involved. The most common serious potential ADEs associated with the interactions were serotonin syndrome, seizures, prolonged QT interval and bleeding.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>An identifiable number of medications, the majority of which are psychotropic, may be involved in MDIs in elderly ambulatory patients which may amplify the risk of serious ADEs. To mitigate the risk, providers will need to pay special attention to the overlapping drug-drug interactions which result in MDIs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12877-021-02594-z","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T10:02:41Z","timestamp":1637316161000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Prevalence of potentially harmful multidrug interactions on medication lists of elderly ambulatory patients"],"prefix":"10.1186","volume":"21","author":[{"given":"Tara V.","family":"Anand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan K.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert S.","family":"Chase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,19]]},"reference":[{"issue":"17","key":"2594_CR1","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1001\/jama.2015.13766","volume":"314","author":"ED Kantor","year":"2015","unstructured":"Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999-2012. JAMA. 2015;314(17):1818\u201330.","journal-title":"JAMA"},{"issue":"1","key":"2594_CR2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","volume":"17","author":"N Masnoon","year":"2017","unstructured":"Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230-.","journal-title":"BMC Geriatr"},{"issue":"11","key":"2594_CR3","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1345\/aph.1A484","volume":"36","author":"IK Bj\u00f6rkman","year":"2002","unstructured":"Bj\u00f6rkman IK. Drug-drug interactions in the elderly. The Annals of Pharmacotherapy. 2002;36(11):1675\u201381.","journal-title":"The Annals of Pharmacotherapy"},{"issue":"3","key":"2594_CR4","doi-asserted-by":"publisher","first-page":"e0118991-e","DOI":"10.1371\/journal.pone.0118991","volume":"10","author":"JJ Sutherland","year":"2015","unstructured":"Sutherland JJ, Daly TM, Liu X, Goldstein K, Johnston JA, Ryan TP. Co-prescription trends in a large cohort of subjects predict substantial drug-drug interactions. PloS one. 2015;10(3):e0118991-e.","journal-title":"PloS one"},{"issue":"6","key":"2594_CR5","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/pds.1351","volume":"16","author":"ML Becker","year":"2007","unstructured":"Becker ML. Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiology and Drug Safety. 2007;16(6):641\u201351.","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"9","key":"2594_CR6","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/jamapsychiatry.2014.436","volume":"71","author":"LM Hampton","year":"2014","unstructured":"Hampton LM, Daubresse M, Chang H-Y, Alexander GC, Budnitz DS. Emergency Department Visits by Adults for Psychiatric Medication Adverse Events. JAMA Psychiatry. 2014;71(9):1006\u201314.","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"2594_CR7","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/jppr.1101","volume":"45","author":"EE Roughead","year":"2015","unstructured":"Roughead EE. Multidrug interactions: the current clinical and pharmacovigilance challenge. Journal of Pharmacy Practice and Research. 2015;45(2):138\u20139.","journal-title":"Journal of Pharmacy Practice and Research"},{"key":"2594_CR8","unstructured":"Cerner Solutions Drug Database [Available from: https:\/\/www.cerner.com\/solutions\/drug-database."},{"issue":"2","key":"2594_CR9","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1137\/0201010","volume":"1","author":"R Tarjan","year":"1972","unstructured":"Tarjan R. Depth-First Search and Linear Graph Algorithms. SIAM Journal on Computing. 1972;1(2):146\u201360.","journal-title":"SIAM Journal on Computing"},{"key":"2594_CR10","unstructured":"Medicare Part D Drug Spending Dashboard & Data [Available from: https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/Information-on-Prescription-Drugs\/MedicarePartD. Accessed 1 July 2021."},{"key":"2594_CR11","doi-asserted-by":"crossref","unstructured":"Watanabe JH. Cost of Prescription Drug-Related Morbidity and Mortality. Ann Pharmacotherapy. 52(9):829\u201337.","DOI":"10.1177\/1060028018765159"},{"key":"2594_CR12","unstructured":"FDA. Preventable Adverse Drug Reactions: A Focus on Drug Interactions FDA2021 [Available from: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/amiodarone-hydrochloride-marketed-cordarone-and-pacerone-information."},{"issue":"1","key":"2594_CR13","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s13104-018-3342-5","volume":"11","author":"R Aljadani","year":"2018","unstructured":"Aljadani R, Aseeri M. Prevalence of drug-drug interactions in geriatric patients at an ambulatory care pharmacy in a tertiary care teaching hospital. BMC Research Notes. 2018;11(1):234-.","journal-title":"BMC Research Notes"},{"issue":"16","key":"2594_CR14","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1056\/NEJMsa020703","volume":"348","author":"TK Gandhi","year":"2003","unstructured":"Gandhi TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E, et al. Adverse drug events in ambulatory care. NEJM. 2003;348(16):1556\u201364.","journal-title":"NEJM"},{"issue":"1","key":"2594_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12913-019-4651-7","volume":"20","author":"H Khalil","year":"2020","unstructured":"Khalil H, Huang C. Adverse drug reactions in primary care: a scoping review. BMC Health Services Research. 2020;20(1):5-.","journal-title":"BMC Health Services Research"},{"key":"2594_CR16","doi-asserted-by":"publisher","unstructured":"Laatikainen O, Sneck S, Bloigu R, Lahtinen M, Lauri T, Turpeinen M. Hospitalizations Due to Adverse Drug Events in the Elderly\u2014A Retrospective Register Study. Front Pharmacol. 2016;7:358. https:\/\/doi.org\/10.3389\/fphar.2016.00358.","DOI":"10.3389\/fphar.2016.00358"},{"issue":"12","key":"2594_CR17","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1007\/s00228-012-1309-3","volume":"68","author":"PR Obreli-Neto","year":"2012","unstructured":"Obreli-Neto PR, Nobili A, de Oliveira Baldoni A, Guidoni CM, de Lyra J\u00fanior DP, Pilger D, et al. Adverse drug reactions caused by drug\u2013drug interactions in elderly outpatients: a prospective cohort study. Eur J Clin Pharmacol. 2012;68(12):1667\u201376.","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"2594_CR18","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s00228-014-1745-3","volume":"70","author":"J Holm","year":"2014","unstructured":"Holm J, Eiermann B, Eliasson E, Mannheimer B. A limited number of prescribed drugs account for the great majority of drug-drug interactions. Eur J Clin Pharmacol. 2014;70(11):1375\u201383.","journal-title":"Eur J Clin Pharmacol"},{"key":"2594_CR19","doi-asserted-by":"crossref","unstructured":"L\u00e9tinier L, Cossin S, Mansiaux Y, Arnaud M, Salvo F, Bezin J, et al. Risk of Drug-Drug Interactions in Out-Hospital Drug Dispensings in France: Results From the DRUG-Drug Interaction Prevalence Study. Front Pharmacol. 2019;10(265).","DOI":"10.3389\/fphar.2019.00265"},{"issue":"4","key":"2594_CR20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2165\/00002512-200825040-00007","volume":"25","author":"LR Tulner","year":"2008","unstructured":"Tulner LR. Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance. Drugs Aging. 2008;25(4):343\u201355.","journal-title":"Drugs Aging"},{"issue":"3","key":"2594_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00787-020-01525-4","volume":"30","author":"SM Jeon","year":"2021","unstructured":"Jeon SM, Park S, Kim D, Kwon J-W. Risk of seizures associated with antipsychotic treatment in pediatrics with psychiatric disorders: a nested case\u2013control study in Korea. European Child & Adolescent Psychiatry. 2021;30(3):391\u20139.","journal-title":"European Child & Adolescent Psychiatry"},{"key":"2594_CR22","unstructured":"Woosley RL, Heise CW, Gallo T, Tate J, Woosley D, Romero KA. QTdrugs List 822 Innovation Park Dr., Oro Valley, AZ 85755: AZCERT, Inc.; [Available from: www.CredibleMeds.org."},{"key":"2594_CR23","doi-asserted-by":"publisher","first-page":"g1626","DOI":"10.1136\/bmj.g1626","volume":"348","author":"NA Buckley","year":"2014","unstructured":"Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ: British Medical Journal. 2014;348:g1626.","journal-title":"BMJ: British Medical Journal"},{"issue":"1","key":"2594_CR24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s12012-017-9416-0","volume":"18","author":"G Frommeyer","year":"2018","unstructured":"Frommeyer G, Fischer C, Ellermann C, Dechering DG, Kochh\u00e4user S, Lange PS, et al. Additive Proarrhythmic Effect of Combined Treatment with QT-Prolonging Agents. Cardiovascular Toxicology. 2018;18(1):84\u201390.","journal-title":"Cardiovascular Toxicology"},{"key":"2594_CR25","doi-asserted-by":"crossref","unstructured":"Isbister GK. The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clinical neuropharmacology.28(5):205\u201314.","DOI":"10.1097\/01.wnf.0000177642.89888.85"},{"issue":"2","key":"2594_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2165\/00002018-200225020-00004","volume":"25","author":"F Pisani","year":"2002","unstructured":"Pisani F. Effects of psychotropic drugs on seizure threshold. Drug Safety. 2002;25(2):91\u2013110.","journal-title":"Drug Safety"},{"issue":"12","key":"2594_CR27","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1177\/106002809502901214","volume":"29","author":"TY Chan","year":"1995","unstructured":"Chan TY. Adverse Interactions Between Warfarin and Nonsteroidal Antiinflammatory Drugs: Mechanisms, Clinical Significance, and Avoidance. Ann Pharmacother. 1995;29(12):1274\u201383.","journal-title":"Ann Pharmacother"},{"issue":"7","key":"2594_CR28","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/S0149-2918(08)80047-1","volume":"30","author":"E Spina","year":"2008","unstructured":"Spina E, Santoro V, D\u2019Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update. Clinical Therapeutics. 2008;30(7):1206\u201327.","journal-title":"Clinical Therapeutics"},{"issue":"1","key":"2594_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2174\/1389200023338017","volume":"3","author":"A Hemeryck","year":"2002","unstructured":"Hemeryck A. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Current Drug Metabolism. 2002;3(1):13\u201337.","journal-title":"Current Drug Metabolism"},{"issue":"1","key":"2594_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s002280050163","volume":"51","author":"U Jeppesen","year":"1996","unstructured":"Jeppesen U. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol. 1996;51(1):73\u20138.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"2594_CR31","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/01.jcp.0000162805.46453.e3","volume":"25","author":"M Kotlyar","year":"2005","unstructured":"Kotlyar M. Inhibition of CYP2D6 activity by bupropion. Journal of Clinical Psychopharmacology. 2005;25(3):226\u20139.","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"10","key":"2594_CR32","first-page":"1176","volume":"28","author":"LM Hesse","year":"2000","unstructured":"Hesse LM. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug metabolism and disposition. 2000;28(10):1176\u201383.","journal-title":"Drug metabolism and disposition"},{"issue":"2","key":"2594_CR33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.amjopharm.2012.01.001","volume":"10","author":"RD Boyce","year":"2012","unstructured":"Boyce RD. Age-related changes in antidepressant pharmacokinetics and potential drug-drug interactions: a comparison of evidence-based literature and package insert information. The American journal of geriatric pharmacotherapy. 2012;10(2):139\u201350.","journal-title":"The American journal of geriatric pharmacotherapy"},{"issue":"9","key":"2594_CR34","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s00228-013-1531-7","volume":"69","author":"S Marusic","year":"2013","unstructured":"Marusic S, Bacic-Vrca V, Obreli Neto PR, Franic M, Erdeljic V, Gojo-Tomic N. Actual drug\u2013drug interactions in elderly patients discharged from internal medicine clinic: a prospective observational study. Eur J Clin Pharmacol. 2013;69(9):1717\u201324.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"2594_CR35","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s11096-017-0439-1","volume":"39","author":"S S\u00e1nchez-Fidalgo","year":"2017","unstructured":"S\u00e1nchez-Fidalgo S, Guzm\u00e1n-Ramos MI, Galv\u00e1n-Banqueri M, Bernabeu-Wittel M, Santos-Ramos B. Prevalence of drug interactions in elderly patients with multimorbidity in primary care. Int J Clin Pharm. 2017;39(2):343\u201353.","journal-title":"Int J Clin Pharm"},{"key":"2594_CR36","doi-asserted-by":"crossref","unstructured":"Glassman PA. The utility of adding retrospective medication profiling to computerized provider order entry in an ambulatory care population. J Am Med Informatics Assoc. 14(4):424\u201331.","DOI":"10.1197\/jamia.M2313"},{"issue":"1","key":"2594_CR37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11606-014-2993-8","volume":"30","author":"W Leiss","year":"2015","unstructured":"Leiss W, M\u00e9an M, Limacher A, Righini M, Jaeger K, Beer H-J, et al. Polypharmacy is Associated with an Increased Risk of Bleeding in Elderly Patients with Venous Thromboembolism. J Gen Intern Med. 2015;30(1):17\u201324.","journal-title":"J Gen Intern Med"},{"issue":"2","key":"2594_CR38","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1001\/jamapsychiatry.2018.3421","volume":"76","author":"WA Ray","year":"2019","unstructured":"Ray WA, Stein CM, Murray KT, Fuchs DC, Patrick SW, Daugherty J, et al. Association of Antipsychotic Treatment With Risk of Unexpected Death Among Children and Youths. JAMA Psychiatry. 2019;76(2):162\u201371.","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"2594_CR39","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/bcp.12829","volume":"81","author":"B Danielsson","year":"2016","unstructured":"Danielsson B, Collin J, Jonasdottir Bergman G, Borg N, Salmi P, Fastbom J. Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults - a Swedish nationwide study. British journal of clinical pharmacology. 2016;81(4):773\u201383.","journal-title":"British journal of clinical pharmacology"},{"issue":"2","key":"2594_CR40","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1517\/14740338.7.2.181","volume":"7","author":"S Sicouri","year":"2008","unstructured":"Sicouri S. Sudden cardiac death secondary to antidepressant and antipsychotic drugs. Expert opinion on drug safety. 2008;7(2):181\u201394.","journal-title":"Expert opinion on drug safety"},{"issue":"3","key":"2594_CR41","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1056\/NEJMoa0806994","volume":"360","author":"WA Ray","year":"2009","unstructured":"Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death. NEJM. 2009;360(3):225\u201335.","journal-title":"NEJM"},{"key":"2594_CR42","doi-asserted-by":"crossref","unstructured":"Schneeweiss S, Avorn J. Antipsychotic Agents and Sudden Cardiac Death \u2014 How Should We Manage the Risk? NEJM. 2009;360(3):294\u20136.","DOI":"10.1056\/NEJMe0809417"},{"issue":"9","key":"2594_CR43","doi-asserted-by":"publisher","first-page":"e1122-9","DOI":"10.4088\/JCP.14m09742","volume":"76","author":"B Risgaard","year":"2015","unstructured":"Risgaard B. Sudden cardiac death in young adults with previous hospital-based psychiatric inpatient and outpatient treatment: a nationwide cohort study from Denmark. The Journal of Clinical Psychiatry. 2015;76(9):e1122-9.","journal-title":"The Journal of Clinical Psychiatry"},{"key":"2594_CR44","doi-asserted-by":"crossref","unstructured":"Simpson TF, Salazar JW, Vittinghoff E, Probert J, Iwahashi A, Olgin JE, et al. Association of QT-Prolonging Medications With Risk of Autopsy-Defined Causes of Sudden Death. JAMA Internal Medicine. 2020.","DOI":"10.1001\/jamainternmed.2020.0148"},{"key":"2594_CR45","doi-asserted-by":"publisher","first-page":"112598","DOI":"10.1016\/j.psychres.2019.112598","volume":"281","author":"J Zhu","year":"2019","unstructured":"Zhu J, Hou W, Xu Y, Ji F, Wang G, Chen C, et al. Antipsychotic drugs and sudden cardiac death: A literature review of the challenges in the prediction, management, and future steps. Psychiatry Research. 2019;281:112598.","journal-title":"Psychiatry Research"},{"key":"2594_CR46","unstructured":"Xiang Y, Albin A, Ren K, Zhang P, Etter JP, Lin S, et al. Efficiently mining Adverse Event Reporting System for multiple drug interactions. AMIA Joint Summits on Translational Science proceedings AMIA Joint Summits on Translational Science. 2014;2014:120-5."},{"issue":"3","key":"2594_CR47","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/1715163516641136","volume":"149","author":"JE Tisdale","year":"2016","unstructured":"Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott). 2016;149(3):139\u201352.","journal-title":"Can Pharm J (Ott)"},{"issue":"6","key":"2594_CR48","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2165\/00002018-200326060-00004","volume":"26","author":"W Yamreudeewong","year":"2003","unstructured":"Yamreudeewong W, DeBisschop M, Martin LG, Lower DL. Potentially Significant Drug Interactions of Class III Antiarrhythmic Drugs. Drug Safety. 2003;26(6):421\u201338.","journal-title":"Drug Safety"},{"issue":"9","key":"2594_CR49","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1093\/jamia\/ocy066","volume":"25","author":"SP Slight","year":"2018","unstructured":"Slight SP, Seger DL, Franz C, Wong A, Bates DW. The national cost of adverse drug events resulting from inappropriate medication-related alert overrides in the United States. J Am Med Inform Assoc. 2018;25(9):1183\u20138.","journal-title":"J Am Med Inform Assoc"},{"key":"2594_CR50","doi-asserted-by":"crossref","unstructured":"Phansalkar S. Drug-drug interactions that should be non-interruptive in order to reduce alert fatigue in electronic health records. Journal of the American Medical Informatics Association: JAMIA.\u00a02013;20(3):489\u201393.","DOI":"10.1136\/amiajnl-2012-001089"},{"issue":"12","key":"2594_CR51","doi-asserted-by":"publisher","first-page":"e8-e18","DOI":"10.1111\/jgs.13807","volume":"63","author":"JT Hanlon","year":"2015","unstructured":"Hanlon JT, Semla TP, Schmader KE. Alternative Medications for Medications in the Use of High-Risk Medications in the Elderly and Potentially Harmful Drug\u2013Disease Interactions in the Elderly Quality Measures. Journal of the American Geriatrics Society. 2015;63(12):e8-e18.","journal-title":"Journal of the American Geriatrics Society"},{"key":"2594_CR52","unstructured":"Amiodarone hydrochloride (marketed as Cordarone and Pacerone) Information [Available from: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/amiodarone-hydrochloride-marketed-cordarone-and-pacerone-information."},{"key":"2594_CR53","doi-asserted-by":"publisher","unstructured":"American Geriatrics Society 2019 Updated AGS Beers Criteria\u00ae for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67:674\u201394. https:\/\/doi.org\/10.1111\/jgs.15767.","DOI":"10.1111\/jgs.15767"},{"issue":"9","key":"2594_CR54","first-page":"CD010106-CD","volume":"2015","author":"JS Furyk","year":"2015","unstructured":"Furyk JS, Meek RA, Egerton-Warburton D. Drugs for the treatment of nausea and vomiting in adults in the emergency department setting. The Cochrane database of systematic reviews. 2015;2015(9):CD010106-CD.","journal-title":"The Cochrane database of systematic reviews"},{"issue":"3","key":"2594_CR55","doi-asserted-by":"publisher","first-page":"e0149984","DOI":"10.1371\/journal.pone.0149984","volume":"11","author":"K Potter","year":"2016","unstructured":"Potter K, Flicker L, Page A, Etherton-Beer C. Deprescribing in Frail Older People: A Randomised Controlled Trial. PLOS ONE. 2016;11(3):e0149984.","journal-title":"PLOS ONE"},{"issue":"1","key":"2594_CR56","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1001\/archgenpsychiatry.2009.175","volume":"67","author":"R Mojtabai","year":"2010","unstructured":"Mojtabai R, Olfson M. National Trends in Psychotropic Medication Polypharmacy in Office-Based Psychiatry. Archives of General Psychiatry. 2010;67(1):26\u201336.","journal-title":"Archives of General Psychiatry"},{"issue":"20","key":"2594_CR57","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1001\/jama.2017.5706","volume":"317","author":"RM Kok","year":"2017","unstructured":"Kok RM, Reynolds CF, III. Management of Depression in Older Adults: A Review. JAMA. 2017;317(20):2114\u201322.","journal-title":"JAMA"},{"issue":"4","key":"2594_CR58","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1177\/0891988707308803","volume":"20","author":"JO Brooks","year":"2007","unstructured":"Brooks JO, Hoblyn JC. Neurocognitive Costs and Benefits of Psychotropic Medications in Older Adults. Journal of Geriatric Psychiatry and Neurology. 2007;20(4):199\u2013214.","journal-title":"Journal of Geriatric Psychiatry and Neurology"},{"issue":"1","key":"2594_CR59","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s12913-019-4064-7","volume":"19","author":"A Petit-Mon\u00e9ger","year":"2019","unstructured":"Petit-Mon\u00e9ger A, Jouhet V, Thiessard F, Berda\u00ef D, Noize P, Gilleron V, et al. Appropriateness of psychotropic drug prescriptions in the elderly: structuring tools based on data extracted from the hospital information system to understand physician practices. BMC Health Services Research. 2019;19(1):272.","journal-title":"BMC Health Services Research"},{"key":"2594_CR60","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1136\/bmj.327.7423.1090","volume":"327","author":"GM Leung","year":"2003","unstructured":"Leung GM, Johnston JM, Tin KYK, Wong IOL, Ho L-M, Lam WWT, et al. Randomised controlled trial of clinical decision support tools to improve learning of evidence based medicine in medical students. BMJ. 2003;327:1090\u20135.","journal-title":"BMJ"},{"issue":"10","key":"2594_CR61","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/pds.4283","volume":"26","author":"KJ Nauta","year":"2017","unstructured":"Nauta KJ, Groenhof F, Schuling J, Hugtenburg JG, van Hout HPJ, Haaijer-Ruskamp FM, et al. Application of the STOPP\/START criteria to a medical record database. Pharmacoepidemiol Drug Saf. 2017;26(10):1242\u20137.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"2594_CR62","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJMra041867","volume":"352","author":"EW Boyer","year":"2005","unstructured":"Boyer EW. The serotonin syndrome. The New England Journal of Medicine. 2005;352(11):1112\u201320.","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"2594_CR63","first-page":"533","volume":"13","author":"J Volpi-Abadie","year":"2013","unstructured":"Volpi-Abadie J, Kaye AM, Kaye AD. Serotonin syndrome. Ochsner J. 2013;13(4):533\u201340.","journal-title":"Ochsner J"},{"issue":"4","key":"2594_CR64","first-page":"121","volume":"51","author":"T Steinert","year":"2017","unstructured":"Steinert T. Epileptic Seizures Under Antidepressive Drug Treatment: Systematic Review. Pharmacopsychiatry. 2017;51(4):121\u201335.","journal-title":"Systematic Review. Pharmacopsychiatry"},{"key":"2594_CR65","doi-asserted-by":"publisher","first-page":"d4551","DOI":"10.1136\/bmj.d4551","volume":"343","author":"C Coupland","year":"2011","unstructured":"Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011;343:d4551.","journal-title":"BMJ"},{"issue":"4","key":"2594_CR66","first-page":"420","volume":"16","author":"A Cipriani","year":"2018","unstructured":"Cipriani A. Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. Focus (American Psychiatric Publishing). 2018;16(4):420\u20139.","journal-title":"Focus (American Psychiatric Publishing)"},{"issue":"3","key":"2594_CR67","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40264-016-0490-1","volume":"40","author":"M-S Ong","year":"2017","unstructured":"Ong M-S, Olson KL, Chadwick L, Liu C, Mandl KD. The Impact of Provider Networks on the Co-Prescriptions of Interacting Drugs: A Claims-Based Analysis. Drug safety. 2017;40(3):263\u201372.","journal-title":"Drug safety"},{"issue":"1","key":"2594_CR68","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/clpt.2009.198","volume":"87","author":"EL Olvey","year":"2010","unstructured":"Olvey EL, Clauschee S, Malone DC. Comparison of Critical Drug\u2013Drug Interaction Listings: The Department of Veterans Affairs Medical System and Standard Reference Compendia. Clinical Pharmacology & Therapeutics. 2010;87(1):48\u201351.","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"2594_CR69","doi-asserted-by":"publisher","unstructured":"Schj\u00f8tt J. Analysis of consensus among drug interaction databases with regard to combinations of psychotropics. Basic Clin Pharmacol Toxicol. 2019;126(2):126\u201332. https:\/\/doi.org\/10.1111\/bcpt.13312.","DOI":"10.1111\/bcpt.13312"},{"key":"2594_CR70","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jbi.2015.04.006","volume":"55","author":"S Ayvaz","year":"2015","unstructured":"Ayvaz S, Horn J, Hassanzadeh O, Zhu Q, Stan J, Tatonetti NP, et al. Toward a complete dataset of drug\u2013drug interaction information from publicly available sources. J Biomed Inform. 2015;55:206\u201317.","journal-title":"J Biomed Inform"},{"issue":"7","key":"2594_CR71","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00228-017-2232-4","volume":"73","author":"N Muhi\u010d","year":"2017","unstructured":"Muhi\u010d N, Mrhar A, Brvar M. Comparative analysis of three drug\u2013drug interaction screening systems against probable clinically relevant drug\u2013drug interactions: a prospective cohort study. Eur J Clin Pharmacol. 2017;73(7):875\u201382.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"2594_CR72","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/jamia\/ocx010","volume":"24","author":"KW Fung","year":"2017","unstructured":"Fung KW, Kapusnik-Uner J, Cunningham J, Higby-Baker S, Bodenreider O. Comparison of three commercial knowledge bases for detection of drug-drug interactions in clinical decision support. J Am Med Inform Assoc. 2017;24(4):806\u201312.","journal-title":"J Am Med Inform Assoc"},{"key":"2594_CR73","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ijmedinf.2017.12.027","volume":"111","author":"P Cornu","year":"2018","unstructured":"Cornu P. High-priority and low-priority drug-drug interactions in different international electronic health record systems: A comparative study. International journal of medical informatics (Shannon, Ireland). 2018;111:165\u201371.","journal-title":"International journal of medical informatics (Shannon, Ireland)"},{"issue":"1","key":"2594_CR74","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/clpt.2011.83","volume":"90","author":"NP Tatonetti","year":"2011","unstructured":"Tatonetti NP, Denny JC, Murphy SN, Fernald GH, Krishnan G, Castro V, et al. Detecting Drug Interactions From Adverse-Event Reports: Interaction Between Paroxetine and Pravastatin Increases Blood Glucose Levels. Clinical Pharmacology & Therapeutics. 2011;90(1):133\u201342.","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"2594_CR75","doi-asserted-by":"crossref","unstructured":"Lorberbaum T, Sampson KJ, Chang JB, Iyer V, Woosley RL, Kass RS, et al. Coupling Data Mining and Laboratory Experiments to Discover Drug Interactions Causing QT Prolongation. J Am Coll Cardiol. 2016;68(16):1756\u201364.","DOI":"10.1016\/j.jacc.2016.07.761"},{"issue":"5","key":"2594_CR76","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40264-016-0393-1","volume":"39","author":"T Lorberbaum","year":"2016","unstructured":"Lorberbaum T, Sampson KJ, Woosley RL, Kass RS, Tatonetti NP. An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval. Drug Saf. 2016;39(5):433\u201341.","journal-title":"Drug Saf"}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-021-02594-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12877-021-02594-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-021-02594-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T13:44:33Z","timestamp":1720791873000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgeriatr.biomedcentral.com\/articles\/10.1186\/s12877-021-02594-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,19]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["2594"],"URL":"https:\/\/doi.org\/10.1186\/s12877-021-02594-z","relation":{},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,19]]},"assertion":[{"value":"13 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Research involving human data was performed in accordance with the Declaration of Helsinki and was approved by the Columbia University Irving Medical Center Institutional Review Board under protocol AAAC8273 \u201cFeasibility of Evaluating Physician Prescribing Patterns\u201d.  Obtaining consent was waived by the CUIMC Institutional Review Board given that it would not be feasible to obtain consent on the thousands of patients used in the study and that using the data posed no risk to the patients.Data for this study was extracted from the New York Presbyterian (NYP) data warehouse. Public access to this database is closed. Permission to obtain the data for this study was granted by the NYP Tripartite Request Assessment Committee (TRAC) which requires a current Institutional Review Board Protocol, HIPAA training, and a secured, encrypted drive for storage.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None (all authors).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"648"}}